SynthesisHuman vaccines & immunotherapeutics2022
Coadministration of seasonal influenza and COVID-19 vaccines: A systematic review of clinical studies.
Synthesis in Human vaccines & immunotherapeutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 54 citations in OpenAlex.
- Behavioral and psychosocial factors associated with coadministration of COVID-19 and influenza vaccines among the elderly.BMC public health · 2026Article
- Short-term safety and reactogenicity of same-day COVID-19 and influenza vaccination in very old, community-dwelling adults.European geriatric medicine · 2026Observational
- What Drives Influenza Vaccination in People with Diabetes? Evidence from the National Health Surveys of 2020 and 2023 in Spain.Epidemiologia (Basel, Switzerland) · 2026Article
- Review
- Immunogenicity and Safety of the COVID-19 Messenger RNA Vaccine Coadministered With Influenza and 23-valent Pneumococcal Polysaccharide Vaccines.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- Partisan differences in healthcare decision-making: Evidence from a vaccine experiment.PloS one · 2026Article
- Harnessing Nanocarriers to Advance Vaccine Development.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026Review
- Safety of co-administration of COVID-19 and seasonal influenza vaccines in individuals with autoimmune diseases from the Canadian National Vaccine Safety Network.Human vaccines & immunotherapeutics · 2025Article
- Determinants of Influenza Vaccine Uptake Among Rural Populations in a Southeastern U.S. State.Vaccines · 2025Article
- Attitudes Toward COVID-19 and Seasonal Influenza Vaccines in the Post-COVID Era: A Cross-Sectional Study Among Adults in Malta.Pharmacy (Basel, Switzerland) · 2025Article
- COVID-19 Vaccination Enhances the Immunogenicity of Seasonal Influenza Vaccination in the Elderly.Vaccines · 2025Article
- Optimal Timing of Vaccination: A Narrative Review of Integrating Strategies for COVID-19, Influenza, and Respiratory Syncytial Virus.Infectious diseases and therapy · 2025Review
- Co-Administration of BNT162b2 COVID-19 and Influenza Vaccines in Adults: A Global Systematic Review.Vaccines · 2025Review
- Adult Vaccine Coadministration Is Safe, Effective, and Acceptable: Results of a Survey of the Literature.Influenza and other respiratory viruses · 2025Review
- Article
- Characteristics of the First Italian Older Adults Vaccinated with an Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine.Medicina (Kaunas, Lithuania) · 2025Article
- The Impact of Vaccination on COVID-19, Influenza, and Respiratory Syncytial Virus-Related Outcomes: A Narrative Review.Infectious diseases and therapy · 2025Review
- Respiratory Virus Vaccines: Pathways to Recommendations and Enhanced Coverage for At-Risk Populations.Infectious diseases and therapy · 2025Article
- Trends in the administration of COVID-19 vaccines with other vaccines in the United States reported to V-safe during December 14, 2020-May 19, 2023.Human vaccines & immunotherapeutics · 2024Article
- Association between combination COVID-19-influenza vaccination and long COVID in middle-aged and older Europeans: A cross-sectional study.Human vaccines & immunotherapeutics · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The lifting of non-pharmaceutical measures preventing transmission of SARS-CoV-2 (and other viruses, including influenza viruses) raises concerns about healthcare resources and fears of an increased number of cases of influenza and COVID-19. For the 2021-2022 influenza season, the WHO and >20 European countries promoted coadministration of influenza and COVID-19 vaccines. Recently, the French Health Authority recommended coupling the COVID-19 vaccination with the 2022-2023 influenza vaccination campaign for healthcare professionals and people at risk of severe COVID-19. The present systematic review examines published data on the safety, immunogenicity, efficacy/effectiveness, and acceptability/acceptance of coadministration of influenza and COVID-19 vaccines. No safety concerns or immune interferences were found whatever the vaccines or the age of vaccinated subjects (65- or 65+). No efficacy/effectiveness data were available. The results should reassure vaccinees and vaccinators in case of coadministration and increase vaccine coverage. Healthcare systems promoting coupled campaigns must provide the necessary means for successful coadministration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.